Abstract 686TiP
Background
ZG006 is a trispecific anti-T cell engager (Tri-TE) targeting Delta-like ligand 3 (DLL3) and CD3, designed to bridge tumor cells and T cells by binding to two distinct DLL3 epitopes on tumor cells and CD3 on T cells, thereby mediating tumor-infiltrating T cell-specific killing of DLL3-expressing tumor cells such as small cell lung cancer and neuroendocrine carcinomas. Based on its molecular structure, ZG006 may have excellent cytotoxic effects against tumors with low DLL3 expression. Preclinical pharmacological and toxicological studies have demonstrated that ZG006 exhibits promising anti-tumor activity and favorable safety profiles both in vitro and in vivo. We have conducted a Phase I clinical study to assess the tolerability, safety, preliminary efficacy of ZG006.
Trial design
This is a multi-center, open-label, Phase I clinical study of ZG006 for the treatment of subjects with advanced small cell lung cancer or neuroendocrine carcinoma who had no standard treatment available, or were intolerant to standard treatment. During the dose escalation stage, an accelerated titration design (ATD) combined with the standard “3+3” design will be used to assess the Recommended Phase 2 Dose (RP2D) for the subsequent studies. Therefore, the dose groups of ZG006 for dose escalations are set as 0.1 mg, 0.3 mg, 1 mg, 3 mg, 10 mg and 30 mg, intravenous administration, once every two weeks. The first 28-day-period was defined as the dose-limiting toxicity (DLT) observation period. After the completion of the DLT observation period, subjects can continue to receive ZG006 treatment until the occurrence of intolerable toxicity, disease progression, initiation of new anti-tumor therapy, withdrawal of consent (whichever comes first). Imaging efficacy assessments are conducted every 6 weeks within 48 weeks post-initial dosing, followed by assessments every 12 weeks thereafter. Tumor response was assessed by RECIST1.1. Pharmacokinetics and DLL3 expressions were also assessed in this study.
Clinical trial identification
NCT05978284.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Suzhou Zelgen BioPharmaceuticals. Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
733P - Efficacy and safety of sacituzumab govitecan (SG) in patients with advanced/metastatic endometrial cancer (EC): Updated results from TROPiCS-03
Presenter: Bradley Corr
Session: Poster session 01
734P - Impact of investigator-assessed response on overall survival (OS) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Presenter: Cara Mathews
Session: Poster session 01
735P - HRD signature (HRDsig) in endometrial cancer (EC)
Presenter: Bhavana Pothuri
Session: Poster session 01
736P - Exceptional clinical benefit (ECB) from immune checkpoint inhibitors (ICIs) in mismatch-repair deficient (MMRd) in recurrent /metastatic endometrial cancer (r/mEC): Are we curing a subset of MMRd EC patients (pts)?
Presenter: Juan Francisco Grau Béjar
Session: Poster session 01
737P - Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study
Presenter: Anna Danska-Bidzinska
Session: Poster session 01
739P - Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial endometrioid adenocarcinoma (EEA)
Presenter: Whitney Grither
Session: Poster session 01
740P - A monocentric analysis of ESCAT gene actionability detection in non-specific molecular profile (NSMP) early-stage endometrial cancer
Presenter: Luca Mastrantoni
Session: Poster session 01
741P - Comparison of the Idylla microsatellite instability (MSI) test with a gold standard MSI test and mismatch repair immunohistochemistry in endometrial cancer
Presenter: Ramona Erber
Session: Poster session 01
743P - Immunotherapy plus chemotherapy in the first-line treatment for primary advanced or recurrent endometrial cancer: An extracted individual patient data and trial-level meta-analysis
Presenter: Mariana Gouveia
Session: Poster session 01